Announcements Trials
Browse Landscape

Status

Completed 3Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 4Myeloid 3Head & Neck 2Gynecologic 2Dermatologic 2Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

avatrombopag 5iron isomaltoside 1000 4hetrombopag 3ferric carboxymaltose 3Cytarabine 3eltrombopag 2Rivaroxaban 2Radiotherapy 2Meropenem 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Erythropoietin 2Cyclophosphamide 2Azacitidine 2thymoglobulin 1stinging nettle lectin 1romiplostim 1raltitrexed 1peppermint oil 1pegfilgrastim 1oprelvekin 1fludarabine phosphate 1fludarabine 1ferrous succinate 1ferrous fumarate 1ferric derisomaltose 1epoetin beta 1cc-486 1Vitamin B 12 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Flow Cytometry × Classical hematology × Clear all
NCT04517175 2020-08-18

Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics?

Maastricht University

Unknown
300 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡